Fig. 7: The clinical relevance of NAS1 expression in human breast tumors. | Nature Communications

Fig. 7: The clinical relevance of NAS1 expression in human breast tumors.

From: Long non-coding RNA NR2F1-AS1 induces breast cancer lung metastatic dormancy by regulating NR2F1 and ΔNp63

Fig. 7

a Expression of NAS1 (upper left) and NR2F1 (lower left) in breast tumors from 13 patients, and quantitation of NR2F1 protein levels in tumors with high or low NAS1 expression (right) (n = 13 patients). b Correlation analyses between NAS1 and EMT-related genes in 837 TCGA breast cancer samples. R, Pearson’s correlation coefficient of the genes to NAS1. c Correlation between NAS1 expression and the ssGSEA scores of E-BCSC, M-BCSC, and EMT signatures in the Fudan cohort47 (n = 447 patients). d Metastasis-free survival analysis of the Qilu breast cancer cohort by NAS1 expression. HR hazard ratio. e Relapse-free survival analysis of the Qilu cohort by NAS1 expression. f, g Metastasis-free survival analyses of NKI cohort75 (n = 295 patients) by ssGSEA scores of gene sets regulated by NAS1 knockdown (f) or NR2F1 overexpression (g). h Schematic model of the mechanism by which NAS1 induces metastatic dormancy of breast cancer cells via NAS1/NR2F1/ΔNp63 axis. Data represent mean ± SD (a). Statistical significance was determined by a two-tailed unpaired t test (a), paired t test (b, c), or two-sided log-rank test (d–g).

Back to article page